GCP
CASI

GSA Capital Partners’s CASI Pharmaceuticals CASI Stock Holding History

GSA Capital Partners’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,857
Closed -$122K – 1458
2021
Q2 		$122K Buy
7,857
+6,213
+378% +$105K 0.01% 1234
2021
Q1 		$39K Sell
1,644
-3,571
-68% -$100K 0.01% 1037
2020
Q4 		$154K Buy
5,215
+3,189
+157% +$69.3K 0.03% 1045
2020
Q3 		$31K Buy
+2,026
New +$38.2K 0.01% 1206

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GSA Capital Partners's CASI Position: Q3 2021 in Review

GSA Capital Partners sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 7,857 shares — an estimated $122K sold.

GSA Capital Partners first reported a position in CASI in Q3 2020 and held it in 4 quarters. The position peaked at $154K in Q4 2020. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

  • GSA Capital Partners reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 7,857 CASI Pharmaceuticals shares in Q3 2021, an estimated $122K.
  • GSA Capital Partners first reported a position in CASI Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • GSA Capital Partners's CASI Pharmaceuticals position peaked at $154K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.